Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Coffers Fill With Funds, But No Money For Reagan-Udall Or Lab Closures

Executive Summary

FDA enters 2008 with the financial wherewithal to go full speed ahead in hiring and establishing the safety programs authorized by the FDA Amendments Act, following President Bush's signing of an omnibus fiscal 2008 appropriations package on Dec. 26

Related Content

Increased FDA China Inspections Backed By House Panel, While Purse Strings Pulled Still Tighter
FDA Post-Market Safety Efforts Won’t Be Impacted By Sentinel In Near Term
FY 2009 Approps Package Will Likely Need To Wait For Next Administration
Reagan-Udall Foundation Approaches The Starting Line; Next Step Is Funding
FDA Commissioner Says Funding Imperils Agency Mission, Modernization
FDA Fiscal 2009 Budget: Will Congress Throw Money After Rhetorical Salvos?
Congressional obstacle for Reagan-Udall Foundation
FDA Takes “Fresh Look” At ORA Reorg, Eyes Outsourcing Some Agency Posts
DTC User Fees Rejected By House Approps Panel As FDA Safety Funds Get Boost
IND Exempt Trials No Longer “Deemed” Covered By Medicare, CMS Says



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts